Drug Profile
Research programme: T-cell therapies - Triumvira
Alternative Names: TAC#921; TAC-921Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Triumvira
- Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Leukaemia; Mantle-cell lymphoma; Multiple myeloma; Ovarian cancer; Precursor B-cell lymphoblastic leukaemia-lymphoma; Solid tumours
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Mantle-cell-lymphoma in Canada (Parenteral)
- 28 Apr 2023 No recent reports of development identified for preclinical development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma in Canada (Parenteral)
- 28 Jul 2020 No recent reports of development identified for preclinical development in Ovarian-cancer in Canada (Parenteral)